Novo Nordisk Solidifies Position with $11 Billion Manufacturing Site Acquisition
Deal News | Jan 07, 2025 | Legal Community Swiss
In a significant transaction, Novo Nordisk has acquired three manufacturing sites from Novo Holdings for $11 billion. The deal includes facilities in Anagni (Italy), Brussels (Belgium), and Bloomington, Indiana (USA), all specializing in the sterile filling of drugs. This acquisition follows Novo Holdings' recent acquisition of Catalent. Swiss law firm Homburger provided comprehensive legal advice to Novo Nordisk on this transaction, involving a team of specialists in corporate, M&A, regulatory, employment, and tax law.
Sectors
- Pharmaceutical
- Legal Services
Geography
- Global – The transaction involves entities from multiple countries, including Denmark, Italy, Belgium, Switzerland, and the USA.
Industry
- Pharmaceutical – The acquisition involves pharmaceutical manufacturing sites specializing in drug production.
- Legal Services – Homburger, a law firm, provided extensive legal advisory services for the transaction.
Financials
- USD 11 billion – The acquisition price paid by Novo Nordisk for the three manufacturing sites.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novo Nordisk | Buyer | Company | A leading global pharmaceutical company specializing in diabetes care and other chronic diseases. |
| Novo Holdings | Seller | Company | The investment arm of the Novo Nordisk Foundation involved in a vast portfolio of life science investments and is the vendor in this transaction. |
| Catalent | Target Company | Company | Previously acquired by Novo Holdings, with manufacturing operations now sold to Novo Nordisk. |
| Homburger | Legal Advisor | Company | A Swiss law firm that provided legal advice to Novo Nordisk for this transaction, involving a multi-disciplinary team. |